# US 2022/0031693 A1 · Tamper Resistant Immediate Release Formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031693 A1
- Document ID: US20220031693A1
- Status: Published application
- Kind: A1
- Application number: 17/501,641
- Filed: 2021-10-14
- Published: 2022-02-03
- Earliest claimed: 2012-03-02
- Assignees: Rhodes Pharmaceuticals L.P.
- Applicants: Rhodes Pharmaceuticals L.P.
- Inventors: Akwete L. Adjei; Sibao Chen; Robert J. Kupper; Vincent Mancinelli
- Web page: https://patentgrep.com/patent/US20220031693A1

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/1635: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/1676: {having a drug-free core with discrete complete coating layer containing drug (adsorbates of liquid drug formulations on inert powders without simultaneous granulation step A61K9/141; with further drug-free outer coating A61K9/5078; drug conjugated to non-active particles A61K47/6921)}
- A61K 9/1682: {Processes}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2846: {Poly(meth)acrylates}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/5078: {with drug-free core}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed in certain embodiments is an immediate release solid oral dosage form comprising a plurality of particles, each particle comprising: (i) a core comprising a first active agent; (ii) a coating comprising a second active agent layered over the core; and (iii) a material that is sensitive to acidic pH layered over the coated core; wherein the dosage form releases at least about 70% of the second active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.

## Claims

### Claim 1

A method of treating pain comprising administering to a patient in need thereof, an immediate release solid oral dosage form comprising a plurality of particles, each particle comprising:
(i) an active agent; and
(ii) a material that is sensitive to acidic pH;
wherein the dosage form releases at least about 70% of the active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.

### Claim 2 (depends on 1)

The method of claim 1, wherein the plurality of particles are dispersed in a matrix.

### Claim 3 (depends on 2)

The method of claim 2, wherein the matrix comprises a gelling agent.

### Claim 4 (depends on 2)

The method of claim 2, wherein the matrix comprises a disintegrant.

### Claim 5 (depends on 2)

The method of claim 2, wherein the matrix comprises a filler.

### Claim 6 (depends on 1)

The method of claim 1, wherein each particle comprises either (I) a core comprising the active agent and the material sensitive to acidic pH layered on the core; or (II) a core comprising a first active agent, a coating comprising a second active agent layered over the core and a material that is sensitive to acidic pH layered over the coated core.

### Claim 7 (depends on 6)

The method of claim 6, wherein the core comprises an inert excipient layered with the active agent.

### Claim 8 (depends on 6)

The method of claim 6, wherein the core comprises the active agent dispersed in a pharmaceutically acceptable excipient.

### Claim 9 (depends on 1)

The method of claim 1, wherein each particle comprises:
(i) a core comprising an inert excipient; and
(ii) a coating comprising both the active agent and the material sensitive to acidic pH layered on the core.

### Claim 10 (depends on 1)

The method of claim 1, wherein each particle comprises the active agent dispersed in the material sensitive to acidic pH.

### Claim 11 (depends on 10)

The method of claim 10, wherein the plurality of particles are in the form of a granulation.

### Claim 12 (depends on 1)

The method of claim 1, wherein the material sensitive to acidic pH is a polymer.

### Claim at position 13

13-15. (canceled)

### Claim 16 (depends on 12)

The method of claim 12, wherein the polymer is a polyacrylate, a polysaccharide, an ion exchange resin, or a mixture thereof.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The method of claim 16, wherein the polyacrylate is a copolymer comprising methyl methacrylate and diethylaminoethyl methacrylate or a copolymer comprising methyl methacrylate, butyl methacrylate and dimethylaminoethyl methacrylate.

### Claim at position 17

-23. (canceled)

### Claim 24 (depends on 3)

The method of claim 3, wherein the gelling agent is selected from the group consisting of sugars, sugar derived alcohols, starch, starch derivatives, cellulose derivatives, attapulgites, bentonites, dextrins, alginates, carrageenan, gums, pectins, gelatin, kaolin, lecithin, magnesium aluminum silicate, carbomers, carbopols, polyvinylpyrrolidone, polyethylene glycol, polyethylene oxide, polyvinyl alcohol, silicon dioxide, curdlan, furcelleran, egg white powder, lacto albumin, soy protein, chitosan, surfactants, emulsifiers, pregelatinized starch, hydroxyethylcellulose, guar gum, xanthan gum, alginate and mixtures thereof.

### Claim at position 19

-36. (canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein the active agent is selected from the group consisting of opioid agonists, tranquilizers, CNS depressants, CNS stimulants, sedative hypnotics, and mixtures thereof.

### Claim 38 (depends on 1)

The method of claim 1, wherein the active agent is an opioid agonist.

### Claim 39 (depends on 38)

The method of claim 38, wherein the opioid agonist is selected from the group consisting of codeine, morphine, oxycodone, oxymorphone, hydrocodone, hydromorphone, pharmaceutically acceptable salts thereof, and mixtures thereof.

### Claim at position 23

-55. (canceled)

### Claim 56 (depends on 1)

The method of claim 1, wherein the dosage form releases at least about 85% of the active agent within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.

### Claim 57

(canceled)

### Claim 58 (depends on 1)

The method of claim 1, wherein the dosage form releases at least about 85% of the active agent within 60 minutes as measured by in- vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml 0.1 N HCl at 37° C.

### Claim at position 27

-102. (canceled)
